Look downward and gently close your Do not rinse the dropper. quinidine, SSRIs) and timolol.Oral beta-adrenergic blocking agents may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. (see Please follow these instructions carefully when using Timolol Maleate Ophthalmic Gel Forming Solution. This may augment the risk of general anesthesia in surgical procedures. The concomitant use of two topical beta-adrenergic blocking agents is not recommended. Timolol has been reported rarely to increase muscle weakness in some patients with myasthenia gravis or myasthenic symptoms.Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures.Patients should also be instructed that ocular solutions, if handled improperly or if the tip of the dispensing container contacts the eye or surrounding structures, can become contaminated by common bacteria known to cause ocular infections. In patients with impaired cardiac function, coadministration should be avoided.Close observation of the patient is recommended when a beta blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension.The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time.Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g. Diese Nebenwirkungen müssen nicht auftreten, können aber. Other topically applied ophthalmic medications should be administered at least 10 minutes before Timolol Maleate Ophthalmic Gel Forming Solution. Gel Forming Solution is supplied as a sterile, isotonic, buffered, aqueous solution of timolol maleate in two dosage strengths. (See Patients should also be advised that if they have ocular surgery or develop an intercurrent ocular condition (e.g., trauma or infection), they should immediately seek their physician's advice concerning the continued use of the present multidose container.Patients should be instructed to invert the closed container and shake once before each use. Due to the physical characteristics of the formulation, there was a higher incidence of transient blurred vision in patients administered Timolol Maleate Ophthalmic Gel Forming Solution. Some patients receiving beta-adrenergic receptor blocking agents have experienced protracted, severe hypotension during anesthesia. Preservative: benzododecinium bromide 0.012%. Protect from light. Increased fetal resorptions were also seen in rabbits at doses of 14,000 times the systemic exposure following the maximum recommended human ophthalmic dose, in this case without apparent maternotoxicity.There are no adequate and well-controlled studies in pregnant women. Timolol Maleate Ophthalmic Gel Forming Solution should not be used alone in the treatment of angle-closure glaucoma.While taking beta-blockers, patients with a history of atopy or a history of severe anaphylactic reactions to a variety of allergens may be more reactive to repeated accidental, diagnostic, or therapeutic challenge with such allergens. Preservative: benzododecinium bromide 0.012%The gel forming solution contains a purified anionic heteropolysaccharide derived from gellan gum. (See Transient blurred vision, generally lasting from 30 seconds to 5 minutes, following instillation, and potential visual disturbances may impair the ability to perform hazardous tasks such as operating machinery or driving a motor vehicle.Patients who are receiving a beta-adrenergic blocking agent orally and Timolol Maleate Ophthalmic Gel Forming Solution should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure.